mobocertinib
Takeda to Withdraw Exkivity Accelerated Approval in EGFR-Mutant NSCLC in US, Globally
The firm said the Phase III confirmatory trial of Exkivity in first-line EGFR exon 20 insertion-positive advanced NSCLC did not meet its primary endpoint.